Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Miyazaki, Yasunari
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype Nov 2023 - Dec 2023 : Acceptance of regulatory submission in China for chronic rhinosinusitis with nasal polyps	Recruiting	3	1700	Europe, Canada, Japan, US, RoW	GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)	GlaxoSmithKline, Iqvia Pty Ltd	Asthma	09/25	09/25
NCT05032066: A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis	Active, not recruiting	2	153	Europe, Canada, Japan, US, RoW	HZN-825, Placebo	Amgen	Idiopathic Pulmonary Fibrosis	06/24	07/25
Kajigaya, Ayako
NCT05032066: A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis	Active, not recruiting	2	153	Europe, Canada, Japan, US, RoW	HZN-825, Placebo	Amgen	Idiopathic Pulmonary Fibrosis	06/24	07/25